Abstract: SB202190 is a well-known p38 mitogen-activated protein kinase (MAPK) inhibitor that has been widely utilized as a critical component in human colorectal organoid culture media to support long-term expansion. However, recent literature highlights that SB202190 possesses a complex pharmacological profile with significant off-target effects that heavily influence cellular behavior, including pathways related to autophagy and ferroptosis. While its primary intended role is p38 inhibition, SB202190 paradoxically amplifies Erk1-2 signaling, alters Wnt/β-catenin pathways, and forces stem cell differentiation at the expense of secretory cell populations. Furthermore, at concentrations typically used in organoid cultures, SB202190 actively induces autophagy and lysosomal biogenesis through PPP3/calcineurin signaling and impacts mitophagy via the inhibition of Cyclin G-associated kinase (GAK). In the context of organoid media, the delicate balance of autophagic processes, such as ferritinophagy, is intimately linked to ferroptosis—an iron-dependent form of cell death. This review synthesizes the current understanding of SB202190's pharmacological activity, its molecular mechanisms concerning autophagy and ferroptosis, and the limitations it imposes on experimental models, emphasizing the need for cautious application in precision medicine and targeted research.
1. Introduction
The establishment of specific culture media has revolutionized the in vitro propagation of human primary cultures, enabling the indefinite expansion of normal and pathological epithelial organoids. A legendary component of the original colorectal organoid medium formula is SB202190, a compound initially selected through empirical screening for its ability to inhibit p38 MAPK [1]. The chronic activation and inhibition of specific signaling pathways by molecules like SB202190 force organoid cells into constrained developmental trajectories. While SB202190 is instrumental in maintaining certain stem cell niches, it introduces highly artificial conditions that are often overlooked in experimental approaches. Notably, SB202190 has been shown to significantly impact intracellular signaling, redox responses, and cellular metabolism. In recent years, the intersection of SB202190's off-target effects with critical cellular degradation and death pathways—specifically autophagy and ferroptosis—has garnered attention. Understanding these interactions is essential for reducing experimental biases in organoid-based assays and improving the reliability of translational research [1].
2. Pharmacological Activity
SB202190 is classically defined as a p38 inhibitor. In the context of colorectal organoids, it is typically administered at concentrations ranging from 3 to 10 µM. The pharmacological inhibition of p38 by SB202190 forces colorectal stem cell differentiation toward enterocytes. Consequently, secretory populations such as Goblet and enteroendocrine cells are no longer represented in the culture, which compromises the physiological development of a multi-population organoid [1].
Despite its classification as a p38 inhibitor, the fundamental pharmacological activity of SB202190 in colorectal organoids is the amplification of Erk1-2 signaling. SB202190 acts as a mimic of the BRAF inhibitor Dabrafenib, leading to a well-documented pharmacological paradox: it induces Erk1-2 agonism in BRAF wild-type cells while causing Erk1-2 inhibition in BRAF-mutated cells. Because of this paradoxical activity, SB202190 strongly alters the baseline pharmacological responsiveness of the cells it is cultured with [1].
3. Molecular Mechanism of Action
The molecular mechanisms of SB202190 extend far beyond p38 inhibition, encompassing a wide array of off-target kinase modulations and direct effects on autophagy and cell survival pathways.
Erk1-2 and Wnt Signaling: The agonist activity of SB202190 on the Erk1-2 pathway does not rely on epidermal growth factor receptor (EGFR) stabilization, as initially thought, but rather on the drug's ability to induce increased BRAF/CRAF dimerization. Furthermore, at a concentration of 1 µM (well below the standard organoid culture dose), SB202190 inhibits GSK3β and CK1δ. The inhibition of these kinases prevents the degradation of β-catenin, leading to its accumulation and the subsequent artifactual amplification of Wnt signaling [1].
Autophagy and Mitophagy: SB202190 directly modulates autophagic pathways. At a concentration of 10 µM, SB202190 induces autophagy and lysosomal biogenesis by activating PPP3/calcineurin signaling. Additionally, SB202190 acts as an off-target inhibitor of Cyclin G-associated kinase (GAK). GAK is involved in clathrin-mediated endocytosis and intracellular trafficking, and it serves as a positive regulator of mitophagy. By inhibiting GAK, SB202190 interferes with the autophagic clearance of mitochondria [1].
Ferroptosis and Ferritinophagy: While SB202190 modulates autophagy, autophagic processes in organoid media are intricately linked to ferroptosis. Ferroptosis is an iron-dependent pathway that induces cell death through non-enzymatic lipid peroxidation, mediated heavily by Transferrin Receptor 1. In organoid cultures, ferritin is degraded via a specific autophagic pathway known as ferritinophagy, which is mediated by nuclear receptor coactivator 4 (NCOA4). The overexpression or activation of NCOA4 depletes cellular ferritin, releasing free ferrous ions that trigger self-propagating lipid peroxidation and subsequent ferroptosis. The complex interplay between SB202190-induced autophagy and the iron-rich environment of organoid media highlights a critical mechanistic axis that dictates cell survival and death [1].
4. Structure-Activity Relationship (SAR)
The provided literature does not contain specific data regarding the chemical structure, functional group modifications, or detailed structure-activity relationship (SAR) studies of SB202190. The focus of the available research is primarily on its phenotypic and signaling effects within complex biological systems rather than its medicinal chemistry properties [1].
5. Current Limitations
The use of SB202190 in experimental models presents several significant limitations and introduces critical biases:
First, SB202190 compromises the physiological cellular diversity of organoids by eliminating secretory cell populations (Goblet and enteroendocrine cells), making it unsuitable for studies requiring a complete, multi-lineage epithelial model. Second, its paradoxical effect on Erk1-2 signaling means that SB202190 must absolutely not be used with BRAF-mutated colorectal cancer organoids, as it will artificially inhibit Erk1-2 and skew drug screening results. Third, its extensive off-target profile—including the inhibition of GSK3β, CK1δ, RIPK2, GAK, MLK2/MAP3K10, and MLK3/MAP3K11—forces cells into constrained and artificial signaling pathways. Finally, its direct induction of autophagy and lysosomal biogenesis via PPP3/calcineurin signaling confounds any experimental setting aimed at studying baseline cellular biochemistry, metabolism, or autophagic/ferroptotic fluxes [1].
6. Future Perspectives
While the original organoid medium formula containing SB202190 remains the gold standard for the indefinite propagation of organoids in vitro, there is a pressing need to develop more focused and reliable culture conditions. Future research must prioritize the elimination or limitation of SB202190 in short-term tests, high-throughput drug screenings, and studies focusing on secretory cells, autophagy, or ferroptosis. By removing such detrimental components, researchers can prevent artifactual resistance or sensitization to specific drugs that do not reflect the actual clinical situation of the patient. The transition toward fully defined, SB202190-free media for specific assays will be crucial for the standardization of organoid models and their successful application in personalized medicine and translational research [1].
